These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28920451)

  • 1. Demonstrating biosimilar and originator antidrug antibody binding comparability in antidrug antibody assays: a practical approach.
    Ryding J; Stahl M; Ullmann M
    Bioanalysis; 2017 Sep; 9(18):1395-1406. PubMed ID: 28920451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.
    Civoli F; Kasinath A; Cai XY; Wadhwa M; Exley A; Oldfield P; Alvandkouhi S; Schaffar G; Chappell J; Bowsher R; Devanarayan V; Marini J; Rebarchak S; Anderson M; Koppenburg V; Lester T
    AAPS J; 2019 Dec; 22(1):7. PubMed ID: 31792633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
    Cai XY; Thomas J; Cullen C; Gouty D
    Bioanalysis; 2012 Sep; 4(17):2169-77. PubMed ID: 23013399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioanalytical challenges of biosimilars.
    Islam R
    Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment.
    Gouty D; Cai CC; Cai XY; Kasinath A; Kumar V; Alvandkouhi S; Yang J; Pederson S; Babbitt B; Peritt D; Rudy A; Koppenburg V; Dasilva A; Ullmann M; Liu S; Satterwhite C
    AAPS J; 2017 Dec; 20(1):25. PubMed ID: 29285735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic verification of bioanalytical similarity between a biosimilar and a reference biotherapeutic: committee recommendations for the development and validation of a single ligand-binding assay to support pharmacokinetic assessments.
    Marini JC; Anderson M; Cai XY; Chappell J; Coffey T; Gouty D; Kasinath A; Koppenburg V; Oldfield P; Rebarchak S; Bowsher RR
    AAPS J; 2014 Nov; 16(6):1149-58. PubMed ID: 25277165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survey of pharmacokinetic bioanalytical methods in biosimilar biological license applications for the assessment of target and antidrug antibody effects.
    Hackel DT; Thway TM; Huang SM; Wang YC
    Bioanalysis; 2021 Sep; 13(17):1323-1332. PubMed ID: 34515515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of pharmacometrics to optimize biosimilar development.
    Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
    J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative immunogenicity assessment: a critical consideration for biosimilar development.
    Liu PM; Zou L; Sadhu C; Shen WD; Nock S
    Bioanalysis; 2015; 7(3):373-81. PubMed ID: 25697194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development.
    Cai XY; Wake A; Gouty D
    Bioanalysis; 2013 Mar; 5(5):517-20. PubMed ID: 23425265
    [No Abstract]   [Full Text] [Related]  

  • 11. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs.
    Colbert A; Umble-Romero A; Prokop S; Chow VF; Wong T; DeSimone D; Zhou L; Pederson S
    MAbs; 2014; 6(5):1178-89. PubMed ID: 25517303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics.
    Barbosa MD; Kumar S; Loughrey H; Singh SK
    Drug Discov Today; 2012 Dec; 17(23-24):1282-8. PubMed ID: 22796124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative multi-tiered immunogenicity assessment of biosimilar pegylated filgrastim: validation of methods for clinical assessment of INTP5.
    Hajela P; Patel R; Kale P; Kumar M; Khambhampaty S
    Expert Opin Biol Ther; 2022 Feb; 22(2):321-330. PubMed ID: 34794342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Analysis of Bioanalytical Method Validation Approaches in Biosimilar Biological Product Development.
    Obianom ON; Thway TM; Schrieber SJ; Okusanya OO; Wang YM; Huang SM; Zineh I
    AAPS J; 2019 Sep; 21(6):105. PubMed ID: 31512109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating biosimilarity and comparability in biotherapeutics.
    Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
    Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in developing antidrug antibody screening assays.
    Dodge R; Daus C; Yaskanin D
    Bioanalysis; 2009 Jul; 1(4):699-704. PubMed ID: 21083131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.
    Cuello HA; Segatori VI; Alberto M; Pesce A; Alonso DF; Gabri MR
    BioDrugs; 2016 Jun; 30(3):225-31. PubMed ID: 27053342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
    Reinisch W; Jahnsen J; Schreiber S; Danese S; Panés J; Balsa A; Park W; Kim J; Lee JU; Yoo DH
    BioDrugs; 2017 Jun; 31(3):223-237. PubMed ID: 28497221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.